Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2610]

WCLC 2022: NADIM II trial provides further support for neoadjuvant chemoimmunotherapy for patients with resectable non-small cell lung cancer

WCLC 2022: NADIM II trial provides further support for neoadjuvant chemoimmunotherapy for patients with resectable...

WCLC 2022: Increased utilization of stereotactic body radiotherapy has decreased treatment disparities for early-stage NSCLC

WCLC 2022: Increased utilization of stereotactic body radiotherapy has decreased treatment disparities for early...

WCLC 2022: Younger patients with NSCLC significantly more likely to be diagnosed with later stages of the disease than older patients

WCLC 2022: Younger patients with NSCLC significantly more likely to be diagnosed with later stages of the...

WCLC 2022: IASLC Early Detection and Screening Committee report on global obstacles to lung cancer screening in low-to middle-income countries

WCLC 2022: IASLC Early Detection and Screening Committee report on global obstacles to lung cancer screening in...

WCLC 2022: Study of lung cancer gene panel testing demonstrates cytological specimens accurate

WCLC 2022: Study of lung cancer gene panel testing demonstrates cytological specimens accurate

WCLC 2022: Study discloses clinical-relevant intertumoural heterogeneity of NSCLC driven by MET exon 14 skipping

WCLC 2022: Study discloses clinical-relevant intertumoural heterogeneity of NSCLC driven by MET exon 14 skipping

WCLC 2022: NELSON trial protocol more sensitive than National Lung Screening trial and may increase the benefits of lung cancer screening

WCLC 2022: NELSON trial protocol more sensitive than National Lung Screening trial and may increase the benefits...

WCLC 2022: National Lung Screening trial finds second primary lung cancer is 4 percent and as high as 8 percent among surgery patients

WCLC 2022: National Lung Screening trial finds second primary lung cancer is 4 percent and as high as 8 percent...

WCLC 2022: Tumour bulk-RNA sequence identifies NSCLC patients at high risk of progression in non-complete pathological responders from NADIM trial

WCLC 2022: Tumour bulk-RNA sequence identifies NSCLC patients at high risk of progression in non-complete...

WCLC 2022: Sotorasib as a lead-in therapy with pembrolizumab or atezolizumab demonstrates durable clinical activity for advanced KRAS p.G12C NSCLC

WCLC 2022: Sotorasib as a lead-in therapy with pembrolizumab or atezolizumab demonstrates durable clinical...

More from ecancer